AIDS Clinical Trials Group study 359 was a controlled study of saquinavir with either ritonavir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons. Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C min ), and virologic response. Concentrations of saquinavir were higher when it was combined with ritonavir than when it was combined with nelfinavir and were lower with adefovir-containing regimens. Females had higher AUC and C min values than did males. Higher saquinavir AUC and C min values were associated with a greater likelihood of human immunodeficiency virus (HIV) RNA levels р500 copies/mL ( ) and were better predictors of response than was the saquinavir inhibitory P p .008 quotient. Males had a lower probability of having HIV RNA levels р500 copies/mL at week 16 than did females (28% vs. 42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels р500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males.
in persons for whom prior therapy had failed. The complete details of the design of ACTG 359 and the week-16 and week-48 results have been published elsewhere [5, 6] . At week 16, only 77 (30%) of 254 patients in ACTG 359 achieved the primary virologic end point of an HIV RNA level р500 copies/mL [5] . Multivariate logistic regression analysis showed that a shorter duration of prior use of indinavir, a treatment regimen that included delavirdine, and female sex were associated with a higher probability of achieving the primary end point. These disappointing rates of virologic success indicate a need to more fully understand the factors that are associated with therapeutic outcome, to develop approaches to improve the response to therapy. ACTG 359 was designed such that the protease inhibitor saquinavir was the common drug in all 6 arms of the study. The objective of the present study was to investigate relationships among concentrations of saquinavir, saquinavir inhibitory quotient (IQ), characteristics of patients, and virologic response.
PATIENTS, MATERIALS, AND METHODS
Study design, selection of patients, study procedures, and pharmacokinetic evaluations. ACTG 359 was a randomized, partially double-blinded, 48-week factorial study of 6 antiretroviral regimens. The regimens were the following: saquinavir soft gelatin capsules (hereafter referred to as saquinavir) plus ritonavir, together with delavirdine (group A), adefovir dipivoxil (group B), or both (group C); and saquinavir plus nelfinavir, together with delavirdine (group D), adefovir dipivoxil (group E), or both (group F). The doses of the antiretroviral agents used in the present study were the following: saquinavir-ritonavir, 400 mg of each drug 2 times daily; saquinavir-nelfinavir, 800 mg and 750 mg, respectively, 3 times daily; delavirdine, 600 mg 2 times daily; and adefovir dipivoxil, 120 mg once daily. The dose of adefovir dipivoxil was reduced to 60 mg once daily after 16 weeks of therapy. In addition, all patients received l-carnitine (500 mg once daily). Patients eligible for ACTG 359 were у16 years old with documented HIV infection who had taken indinavir with 2 nucleoside reverse-transcriptase inhibitors for at least 6 months, remained receiving treatment for the 2 weeks immediately before entry in the study, and had screening plasma HIV RNA levels of 2000-200,000 copies/mL (Amplicor HIV Monitor Test, version 1.0; Roche Diagnostic Systems; lower limit of quantification, 500 copies/mL). Patients had never taken nonnucleoside reverse-transcriptase inhibitors or adefovir dipivoxil. The institutional review boards at each site approved this study, and all patients provided written, informed consent.
Study participants had study visits every 4 weeks through week 48. At each visit, clinical assessments and laboratory tests were performed. Blood samples for determination of HIV RNA levels in plasma (Amplicor HIV Monitor Test) were obtained every 4 weeks through week 16 and every 8 weeks through week 48. A subgroup of the study population, selected by stratified, simple, random sampling without replacement, underwent phenotypic resistance testing at baseline (PhenoSense assay; ViroLogic). One blood sample for quantitation of concentrations of saquinavir was obtained from all study participants at weeks 4, 8, and 16. In addition, at 1 of these visits, which was randomly selected by the site, a second blood sample was obtained at least 1 h after the first. These blood samples were obtained at random times after unobserved doses. Patients provided the times of taking their last 3 doses of study medications, which were recorded along with the time that the blood samples were obtained. The first 7 patients enrolled in each of the 6 treatment arms from the 10 sites participating in ACTG 359 were entered in a intensive pharmacokinetic evaluation at week 2, in which blood samples were obtained before administration of the regimens and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h after administration. The details and results of the intensive pharmacokinetic evaluation have been published elsewhere [7] . Plasma was obtained and was frozen at Ϫ70ЊC until analyzed.
Plasma concentrations of saquinavir were measured by use of a validated, quality-controlled high-performance liquid chromatography technique that simultaneously quantitated the concentrations of saquinavir, ritonavir, nelfinavir, and delavirdine [8] . The lower limits of detection were 20 ng/mL for saquinavir, ritonavir, nelfinavir, and delavirdine. Within-run accuracy for quality-control samples ranged from Ϫ6% to +8%, with coefficients of variation ranging from 2% to 8%.
All concentration-time data for all patients were appropriately pooled and analyzed by use of a nonlinear mixed-effects regression model [9] . The structural pharmacokinetic model was a first-order absorption, first-order elimination 1-compartment model; the error model was a combined proportional/additive model. By use of the first-order conditional estimation procedure, Bayesian estimates of individual pharmacokinetic parameters were obtained, in addition to the population means and variances. The individualized parameters were used to estimate the corresponding 24-h area under the curve (AUC) and trough concentrations (C min ; either 8 h or 12 h after administration, as appropriate for the regimen) for saquinavir. The covariate analysis used a forward-inclusion/backward-elimination approach. Statistical significance was set at (x 2 test).
The IQ for saquinavir was expressed as the ratio of exposure to saquinavir to baseline phenotypic susceptibility to saquinavir. The binding of saquinavir to plasma proteins was not measured, and no correction factor was used. In the calculation of the IQ, 2 model-derived pharmacokinetic parameters of saquinavir were considered, AUC (mg ϫ h/L) and C min (mg/L), as were 2 measures of phenotypic susceptibility, the IC 50 (ng/mL) and the fold change (FC) in IC 50 , where FC was determined as the patient's IC 50 relative to that of control wild-type virus. Four saquinavir IQ measurements were calculated for each patient: (1) IQ AUC , (2) IQ Cmin , (3) IQFC AUC , and (4) IQFC Cmin , where IQ refers to the phenotype expressed as the IC 50 and IQFC refers to the phenotype expressed as the FC.
Statistical analyses. All statistical analyses were based on subsets of patients for whom complete data of the variables involved were available. If not otherwise specified in Results, the sample size was 186. Wherever appropriate, continuous and categorical variables were compared by use of Kruskal-Wallis tests and x 2 tests, respectively, among different groups of patients. The primary virologic end point was the proportion of patients with HIV RNA levels р500 copies/mL at week 16. For each patient, the HIV RNA result closest to week 16 between study weeks 14 and 20 was used to determine the value of the primary virologic end point. Logistic regression models were used to evaluate the association between the primary virologic end point and saquinavir pharmacokinetic parameters and baseline characteristics of patients. HIV RNA levels at week 4, 8, 12 , and 16 were determined by use of HIV RNA levels measured during each visit window, which extends from the midpoint of previous and current scheduled visits to the midpoint of current and next scheduled visits. The lowest HIV RNA level at weeks 4, 8, 12, or 16 was designated as the nadir HIV RNA level. Any values that were р500 copies/mL were considered as left-censored at 500 copies/mL. Censored regression models were used to relate the nadir HIV RNA level to other variables of characteristics of patients by assuming normality in the distribution of the response variable. The potential dependence between the model-derived saquinavir population pharmacokinetic parameters was ignored in the analyses as the standard 2-sample tests were still found to be valid [10] . Receiver operating characteristic (ROC) curves and classification and regression trees (CART) methods were used to identify potential thresholds of concentrations of saquinavir that best discriminate virologic outcomes.
RESULTS
A total of 277 patients were randomized to 1 of the 6 treatment arms in ACTG 359. Pharmacokinetic data were available for 186 persons. The characteristics of this subset of patients are summarized in table 1. Baseline characteristics were not different between patients who underwent pharmacokinetic evaluations ( ) and those who did not ( ), with the n p 186 n p 91 exception of the duration of prior zidovudine and lamivudine use (table 1) .
Saquinavir pharmacokinetic characteristics. Concentrations of saquinavir were quantitated in 1022 blood samples obtained from 186 patients. A descriptive analysis of the saquinavir pharmacokinetic parameters is given in table 2. Concentrations of saquinavir are shown in figure 1. There were no statistically significant differences between the racial/ethnic groups and concentrations of saquinavir. The AUC and C min values of saquinavir were significantly higher when saquinavir was combined with ritonavir (arms A, B, and C) than when it was combined with nelfinavir (arms D, E, and F) ( for AUC and P p .0006 P p for C min , Kruskal-Wallis test). The population pharma-.0004 cokinetic analysis indicated that saquinavir bioavailability was increased 90% and clearance was reduced 37%, with ritonavir coadministration, compared with nelfinavir. The typical elimination half-life of saquinavir, when saquinavir was given with ritonavir, was 4.5 h, compared with 2.8 h, when saquinavir was given with nelfinavir. The clearance of saquinavir was increased 49% in the presence of adefovir. When the treatment arms were grouped according to whether saquinavir was combined with delavirdine (arms A and D), adefovir (arms B and E), or both delavirdine and adefovir (arms C and F), concentrations of saquinavir were significantly lower in patients whose regimen included adefovir ( for AUC and for C min , P p .003 P p .0008 Kruskal-Wallis test).
Concentrations of saquinavir and HIV RNA responses. Week-16 HIV RNA specimens were not available for 6 of the 186 patients. A total of 50 (28%) of the remaining 180 patients had an HIV RNA level р500 copies/mL at week 16. Median saquinavir AUC and C min values for those patients who had HIV RNA levels р500 copies/mL at week 16 were 19.2 mg ϫ h/L and 0.23 mg/L, respectively, compared with 14.5 mg ϫ h/ L and 0.13 mg/L, respectively, for those who had levels 1500 copies/mL. Both univariate and multivariate logistic regression analyses demonstrated that exposure to saquinavir significantly influenced the primary virologic end point. A higher saquinavir AUC or C min value was associated with a greater likelihood of achieving an HIV RNA level р500 copies/mL at week 16 (P ). ROC n p 186 curves and discrimination trees were plotted to investigate saquinavir AUC and C min virologic response thresholds. For both AUC and C min , the ROC curves were close to the diagonal line, providing no ability to identify threshold concentrations. The discrimination trees, however, did provide information on concentration values associated with response ( figure 2) . In both the AUC and C min CART analysis, the first tree split occurred at a baseline HIV RNA level of 4.3 log 10 copies/mL. For the subgroup of 114 patients with HIV RNA levels у4.3 log 10 copies/ mL, a saquinavir AUC value of 25 mg ϫ h/L was the second split; 11 (42%) of 26 patients with an AUC value у25 mg ϫ h/ L had an HIV RNA level р500 copies/mL at week 16, compared with 10 (11%) of 88 patients who had an AUC value !25 mg ϫ h/L. Of 78 patients with a baseline HIV RNA level у4.3 log 10 copies/mL and a C min value у0.1 mg/L, 21 (27%) of 78 had an HIV RNA level р500 copies/mL at week 16, compared with none (0%) of 36 patients who had a C min value !0.1 mg/L.
Saquinavir IQ and HIV RNA responses. Of the 186 persons for whom pharmacokinetic data were available, baseline phenotypic susceptibility to saquinavir was determined in 114 randomly selected patients. The median IC 50 to saquinavir was 1.34 nmol/L (interquartile range [IQR], 1.34-3.36; median, 0.90 ng/mL; IQR, 0.9-2.25 ng/mL), and the median FC was 0.88 (IQR, 0.66-2.27). As described above, 4 versions of the saquinavir IQ were considered; the characteristics of these 4 variables are given in table 3. Univariate logistic regression analysis demonstrated that IQFC AUC was a statistically significant predictor ( ) of the primary virologic end point. IQFC AUC P p .03 remained statistically significant ( ) in predicting the P p .05 week-16 HIV RNA response, even after adjusting for the effect of baseline HIV RNA and whether the regimen excluded delavirdine or not (arms B and E vs. other arms). Both models showed that, for each unit increase in IQFC AUC , the odds of having an HIV RNA level р500 copies/mL at week 16 increased by ∼2%. None of the remaining versions of IQ variables were statistically significant predictors of the primary HIV RNA response in univariate or multivariate logistic regression analyses.
Univariate and multivariate logistic regression analyses indicated that IQFC AUC and IQ AUC were highly statistically significant predictors of nadir HIV RNA levels during the first 16 weeks after entry in the study ( and , respectively, P p .0004 P p .003 multivariate analyses). IQ Cmin was not statistically significant ( ) in either model. IQFC Cmin , however, was a marginally P 1 .05 significant predictor of the nadir HIV RNA response in both univariate and multivariate regression models ( and P p .04 , respectively). All models demonstrated that, during P p .046 Figure 2 . Saquinavir area under the curve (AUC) and trough concentration (C min ) classification and regression trees. In both the AUC and C min trees, the first split occurred at baseline (HIV RNA level, 4.3 log 10 copies/mL). For the subgroup of 114 patients with HIV RNA levels у4.3 log 10 copies/mL, a saquinavir AUC value of 25 mg ϫ h/L or a C min value of 0.1 mg/L was the second split. The discrimination trees show that 11 (42%) of 26 patients with an AUC value у25 mg ϫ h/L had an HIV RNA level р500 copies/mL at week 16, compared with 10 (11%) of 88 patients who had an AUC value !25 mg ϫ h/L. Of 78 patients with baseline HIV RNA levels у4.3 log 10 copies/mL and C min values у0.1 mg/L, 21 (27%) of 78 had HIV RNA levels р500 copies/mL at week 16, compared with none (0%) of 36 patients who had a C min value !0.1 mg/L. first 16 weeks of therapy, a higher saquinavir IQ corresponded with a lower HIV RNA level. For example, each unit increase in IQFC AUC resulted in an ∼0.024 log 10 decrease in nadir HIV RNA level. After adjusting for the effect of baseline HIV RNA and whether the regimen included adefovir, each unit increase in IQFC AUC corresponded with a ∼0.022 log 10 decrease in nadir HIV RNA level.
Sex-based effect on concentrations of saquinavir, IQ, and HIV RNA responses. In the present study, females had statistically higher concentrations of saquinavir than did males (table 2). The median AUC value in females was 20.0 mg ϫ h/L, compared with 14.9 mg ϫ h/L in males ( ). The P p .004 median C min value in females was 0.30 mg/L, compared with 0.13 mg/L in males ( ). The typical value of saquinavir P p .0001 clearance in females was 47% of that of males, after adjustment for body weight. At baseline, no significant difference in HIV RNA level or phenotypic susceptibility to saquinavir and indinavir was found between male and female patients. With respect to the 4 saquinavir IQ variables, females had higher IQ levels than males, with all except the IQFC AUC being significantly different (table 3) . Sex had a statistically significant effect on the week-16 HIV RNA response. Males had a lower probability of having an HIV RNA level р500 copies/mL at week 16 
females).
Multivariate logistic regression analysis found that sex was an independent predictor of the primary HIV RNA response, after adjustment for baseline HIV RNA level, baseline weight, and whether the regimen excluded delavirdine. The adjusted odds ratio between males and females at week 16 was 0.43 ( ; ). P p .04 n p 247
DISCUSSION
We found that concentrations of saquinavir were a significant predictor of virologic response in an indinavir-experienced population. In the present study, concentrations of saquinavir were significantly higher when saquinavir was combined with ritonavir than when it was combined with nelfinavir and were lower in the presence of adefovir or adefovir plus delavirdine than in the presence of delavirdine. Higher saquinavir AUC and C min values were associated with a greater likelihood of achieving HIV RNA levels р500 copies/mL at week 16, as well as a greater reduction in HIV RNA levels at weeks 4, 8, 12, or 16. Females had significantly higher concentrations of saquinavir than did males, and, consistent with the relationship between exposure to saquinavir and virologic response, a greater proportion of females than males had HIV RNA values р500 copies/mL at week 16. These new findings advance our knowledge of the clinical pharmacologic profile of saquinavir. The observation that significant sex-based differences in virologic response can arise because of sex-based differences in pharmacokinetics also expands our understanding of the reasons why antiretroviral therapy may fail for patients.
In the design of ACTG 359, the initial choice of saquinavir doses to combine with ritonavir or nelfinavir was based on drug-drug interaction studies that demonstrated that ritonavir is a more potent inhibitor of the metabolism of saquinavir than is nelfinavir [11, 12] . Therefore, saquinavir was given in a higher daily dose and 3 times daily when administered with nelfinavir, compared with 2 times daily when administered with ritonavir. Nevertheless, concentrations of saquinavir were significantly higher when saquinavir was combined with ritonavir than when it was combined with nelfinavir. Therefore, from the perspective of combining saquinavir with a metabolic inhibitor, to enhance its concentrations and convenience to patients, ritonavir is preferable to nelfinavir.
The finding of an adverse drug-drug interaction between saquinavir and adefovir was unexpected, and the mechanism is not obvious; induction of P-glycoprotein has been hypothesized to explain the decrease in concentrations of saquinavir [7] . A similar interaction between tenofovir disoproxil fumarate, an adefovir-related compound, and atazanavir, in which the C min value of atazanavir was reduced 40%, has recently been described (Bristol-Myers Squibb Pharmaceutical Research Institute, letter). An intensive pharmacokinetic evaluation was conducted for 37 participants in ACTG 359, in which observed doses were administered at steady state, and concentrations were measured for 12 h after administration. This intensive substudy found that both concentrations of saquinavir and concentrations of delavirdine were significantly lower when each was given with adefovir than when each was given without adefovir. The present pharmacokinetic data, obtained by use of a sparse sampling strategy on a large number of patients, confirm the observations of the intensive study. Importantly, these data on concentrations of saquinavir help to explain the findings of the overall parent study: that the delavirdine-containing regimens elicited better virologic responses than did the adefovir-containing regimens, despite all patients being naive to both drugs. The explanation provided by these pharmacokinetic studies is that an adverse drug-drug interaction among saquinavir, adefovir, and delavirdine lowered concentrations of saquinavir and thereby diminished virologic response.
Concentrations of saquinavir significantly influenced virologic response. Higher saquinavir AUC and C min values correlated with a greater likelihood of achieving HIV RNA levels р500 copies/mL at week 16 and with lower HIV RNA levels during the first 16 weeks after entry in the study. CART analyses indicated that AUC values 125 mg ϫ h/L and C min values 10.1 mg/L provided higher rates of virologic response. A saquinavir C min value of 0.1 mg/L for a threshold value is in agreement with the suggestions of other investigators [13] . These data reaffirm the pharmacologic principle, supported by numerous investigations of antiretroviral agents, that response is related to the concentration of drug in the body [14, 15] . The IQ expressed in the present study as the ratio of exposure to saquinavir to baseline phenotypic susceptibility to saquinavir was investigated as a determinant of virologic response, because it integrates the concentration of drug in the body with the concentration necessary to inhibit viral replication and might lead to an improved understanding of concentration-response relationships [16] . For example, an analysis of the IQ for lopinavir/ritonavir and efavirenz in treatment-experienced persons found that the pharmacokinetic characteristics themselves (AUC and C min values) were not significant predictors of response, whereas the IQ values for lopinavir and efavirenz were [17] . In ACTG 359, 4 versions of the IQ were evaluated. Only the IQ using phenotypic FC for susceptibility and AUC for drug concentration (IQFC AUC ) was a statistically significant predictor of the primary virologic end point; none of the other IQ variables, including those that used saquinavir C min , were statistically significant predictors of the primary HIV RNA response in univariate or multivariate logistic regression analyses. The lack of ability of IQ to predict virologic response in the present study may have arisen because all virus isolates at entry in the study demonstrated phenotypic susceptibility to saquinavir, as evidenced by a median FC in susceptibility of 0.88. Although the notion of the IQ remains appealing, these data raise questions about the across-the-board utility of this metric and about which pharmacokinetic characteristic is the most informative.
Concentrations of saquinavir were significantly higher in females than in males. The clearance of saquinavir in females was approximately 50% of that in males, after adjustment for body weight. Females also had higher IQ values than did males. The sex-based differences in exposure to saquinavir were clinically significant-females were approximately twice as likely than males to achieve an HIV RNA level р500 copies/mL at week 16. The manufacturer has reported that there was no sexbased difference in saquinavir (soft gelatin capsule) concentrations following a single-dose (1200 mg) study of 12 female and 18 healthy male volunteers [18] . It is uncertain, however, whether the single-dose, non-steady-state design was suitable to discover sex-based differences for this agent, because of the processes that produce ∼2-fold higher concentrations of saquinavir at steady state than after a single dose.
Saquinavir is a substrate for both cytochrome P450 (CYP) 3A4 and P-glycoprotein, and its low bioavailability is a result of the combined effects of limited absorption and intestinal and hepatic first-pass metabolism [18] [19] [20] . Sex-based differences in concentrations of other such substrates have been demonstrated. For example, an investigation of midazolam as a selective probe for intestinal CYP3A activity demonstrated a faster systemic and oral clearance in women not receiving oral contraceptives than in men. [21] In contrast, the apparent oral clearance of verapamil, a mixed CYP3A and P-glycoprotein substrate (like saquinavir), was found to be slower in women than in men [22, 23] . These findings might indicate that the basis for the sex-based difference in concentrations of saquinavir arises as a consequence of expression or function of Pglycoprotein. Among other antiretroviral drugs, the oral clearance of nevirapine has been shown to be slower in women than in men. [24] Interestingly, an analysis of data from bioequivalence studies submitted to the Food and Drug Administration demonstrated statistically significant sex-based differences in ∼28% of the data sets [25] . The extent of sex-based differences in pharmacologic characteristics of antiretroviral agents is not known, since these issues have received little rigorous study, and women often were underrepresented in the available studies. These data provide a compelling argument that trial designs with sufficient power to allow investigations of sex-based differences in pharmacokinetics and pharmacodynamics should be routinely employed in the development of antiretroviral drugs.
This investigation of concentrations of saquinavir, characteristics of patients, and virologic response has provided convincing evidence that sex is a statistically significant determinant of concentrations of saquinavir and that concentrations of saquinavir are a statistically and clinically significant determinant of virologic response. As a consequence, males, as well as any patient who has low concentrations of saquinavir, are at an increased risk for virologic failure. The implications for these findings might be to administer a higher dose of saquinavir to males than to females. However, concentrations of saquinavir are highly variable; in these participants, there was 1400-fold variability in C min values. Thus, it is not certain that this strategy would provide sufficiently high concentrations to protect against failure for all males, and this strategy would do nothing for those females who have low concentrations. Therapeuticdrug monitoring has been suggested as a strategy to improve the response and/or to minimize the toxicity associated with antiretroviral agents [13, 26, 27] . Two prospective studies have now demonstrated that concentration-guided dosing leads to a greater proportion of patients achieving undetectable levels of HIV RNA, compared with those who receive standard dose therapy [28, 29] . The pharmacokinetic challenges illustrated by this investigation of highly variable concentrations among patients, sex-based differences in pharmacokinetics, and the dependence of virologic response on adequate concentrations are ones that could be addressed by a therapeutic-drug monitoring approach. It is acknowledged that antiretroviral therapy is already complex. However, therapeutic failure with antiretroviral regimens is still too common, and any therapeutic maneuver that might assist the clinician in improving the likelihood of response should be aggressively investigated to determine whether it plays a role in the treatment of patients.
